Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:varicella-zoster_virus
|
| gptkbp:age |
second dose at 4-6 years
first dose at 12-15 months 12 months to 12 years |
| gptkbp:approves |
gptkb:1995
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
-15° C or lower
|
| gptkbp:clinical_trial |
conducted before approval
|
| gptkbp:contraindication |
pregnancy
immunocompromised individuals history of severe allergic reaction to vaccine components |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
two doses
not routinely recommended |
| gptkbp:healthcare |
important for preventing outbreaks
reduced incidence of chickenpox |
| https://www.w3.org/2000/01/rdf-schema#label |
varicella vaccine
|
| gptkbp:is_effective_against |
about 90% effective
|
| gptkbp:is_vulnerable_to |
varies by region
updated periodically varies by country requires refrigeration long-lasting immunity monitored for safety ongoing studies on long-term effects administered by healthcare professionals attenuated live virus part of childhood immunization schedule available from health departments high effectiveness in preventing severe disease introduced in the US in 1995 protects unvaccinated individuals significantly reduced hospitalizations studies on vaccine safety continue reduced healthcare costs associated with chickenpox |
| gptkbp:manager |
subcutaneous
|
| gptkbp:mythology |
debunked by health authorities
|
| gptkbp:price |
varies by country
|
| gptkbp:side_effect |
fever
rare serious allergic reactions decreased mortality from chickenpox mild rash tenderness at injection site |
| gptkbp:suitable_for |
gptkb:CDC
gptkb:WHO |
| gptkbp:targets |
chickenpox
|
| gptkbp:type |
live attenuated vaccine
|
| gptkbp:variant |
MMRV vaccine
|